- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.01. | Greenwich LifeSciences reports $12.5 million cash balance | 2 | Investing.com | ||
| 27.01. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy | 125 | GlobeNewswire (Europe) | STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 26.01. | Greenwich LifeSciences-Aktie: Wird sie zum Impfstoff-Überflieger? | 268 | sharedeals.de | Die Aktie von Greenwich LifeSciences sorgte kürzlich mit einem Unternehmensupdate für neue Aufmerksamkeit. Ausschlaggebend ist weniger ein klinischer Meilenstein als vielmehr ein regulatorischer Fortschritt... ► Artikel lesen | |
| 22.01. | GLSI Stock Surges After FDA Clears Use Of Commercial GP2 In Phase III Trial | 1 | RTTNews | ||
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.01. | Greenwich LifeSciences: Kurssprung nach FDA-Zulassung für kommerzielle Charge in Phase-III-Studie | 16 | Investing.com Deutsch | ||
| 22.01. | Greenwich LifeSciences surges as FDA clears commercially manufactured product candidate | 1 | Seeking Alpha | ||
| 22.01. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 | 822 | GlobeNewswire (Europe) | STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 29.12.25 | Greenwich LifeSciences: Aktie legt nach verlängerter Insider-Sperrfrist kräftig zu | 5 | Investing.com Deutsch | ||
| 29.12.25 | Greenwich LifeSciences verlängert Haltefrist für Insider-Aktien bis September 2026 | 3 | Investing.com Deutsch | ||
| 29.12.25 | Greenwich LifeSciences extends insider share lock-up to Sept 2026 | 1 | Investing.com | ||
| 29.12.25 | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 | 1 | GlobeNewswire (USA) | ||
| 26.12.25 | What's Going On With Greenwich LifeSciences Friday? | 1 | Benzinga.com | ||
| 22.12.25 | Greenwich LifeSciences: Positive Studiendaten zu Brustkrebs-Immuntherapie treiben Aktie an | 1 | Investing.com Deutsch | ||
| 22.12.25 | Greenwich LifeSciences provides updates on Phase III breast cancer trial | 2 | Investing.com | ||
| 22.12.25 | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy | 750 | GlobeNewswire (Europe) | STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 18.12.25 | Greenwich LifeSciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.12.25 | Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine? | 1 | Benzinga.com | ||
| 15.12.25 | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 | 180 | GlobeNewswire (Europe) | STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 08.12.25 | Greenwich LifeSciences: Rekrutierung für Phase-III-Studienarm zu Brustkrebs-Immuntherapie abgeschlossen | 1 | Investing.com Deutsch | ||
| 08.12.25 | Greenwich LifeSciences completes enrollment in Phase III trial arm | 2 | Investing.com |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| KUROS BIOSCIENCES | 27,620 | +0,07 % | KUROS BIOSCIENCES AG - Stärke in der Ruhephase | ||
| ABIVAX | 98,30 | -0,30 % | ABIVAX Société Anonyme (ABVX): A Bull Case Theory | ||
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,114 | -1,45 % | Iovance Biotherapeutics, Inc.: Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma | SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal... ► Artikel lesen | |
| DENALI THERAPEUTICS | 17,655 | -0,93 % | Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement | WASHINGTON (dpa-AFX) - Denali Therapeutics Inc. (DNLI) and Royalty Pharma plc (RPRX) on Thursday announced a $275 million synthetic royalty funding agreement tied to future net sales of Tividenofusp... ► Artikel lesen | |
| ARGENX | 688,00 | -0,03 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Argenx nach Eckdaten für 2025 auf "Hold" mit einem Kursziel von 675 Euro belassen. Der Umsatz mit dem Medikament Vyvgart... ► Artikel lesen | |
| INSMED | 127,00 | 0,00 % | Insmed Incorporated: Insmed Provides Clinical and Business Update | -Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues... ► Artikel lesen | |
| CAPRICOR | 19,000 | -9,31 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,200 | -1,37 % | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | ||
| REVOLUTION MEDICINES | 83,00 | +0,61 % | Revolution Medicines, Inc.: Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor | REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,500 | -1,69 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| CORVUS PHARMACEUTICALS | 16,040 | -7,39 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M | SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock |
GREENWICH LIFESCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +3,630 (+14,41 %) liegt der Kurs bei 28,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.